非洛地平缓释片联合赖诺普利氢氯噻嗪片治疗中重度原发性高血压患者的效果分析  

Effect Analysis of Felodipine Sustained-Release Tablets Combined with Lisinopril and Hydrochlorothiazide Tablets in the Treatment of Patients with Moderate and Severe Essential Hypertension

作　　者：黄璐 孔德皓 滕韵 HUANG Lu;KONG Dehao;TENG Yun(Department of Geriatrics,Weining Yi Hui Miao Autonomous County People’s Hospital,Bijie 553100,China)

机构地区：[1]贵州省威宁彝族回族苗族自治县人民医院老年医学科,贵州毕节553100

出　　处：《中国伤残医学》2024年第17期96-98,共3页Chinese Journal of Trauma and Disability Medicine

摘　　要：目的:分析非洛地平缓释片联合赖诺普利氢氯噻嗪片治疗中重度原发性高血压患者的效果和安全性。方法:选择2022年9月—2023年9月威宁彝族回族苗族自治县人民医院收治的70例中重度原发性高血压患者作为研究对象,随机将其分为研究组和对照组,各35例。研究组采用非洛地平缓释片联合赖诺普利氢氯噻嗪片治疗,对照组采用非洛地平缓释片联合盐酸贝那普利片治疗,比较两组的血压水平、治疗总有效率及不良反应发生情况。结果:治疗6个月后,研究组收缩压(123.58±10.36)mmHg、舒张压(80.14±5.07)mmHg,分别低于对照组的(162.37±15.24)mmHg、(94.02±90.18)mmHg,研究组治疗总有效率97.14%高于对照组的82.86%,研究组不良反应发生率2.86%低于对照组的14.29%,差异均有统计学意义(P<0.05)。结论:赖诺普利氢氯噻嗪片治疗中重度原发性高血压患者,能取得良好的治疗效果,降压明显且具有一定安全性。Objective:To analyze the efficacy and safety of Felodipine Sustained-Release Tablets Combined with Lisinopril and Hydrochlorothiazide Tablets in the treatment of patients with moderate and severe essential hypertension.Methods:A total of 70 patients with moderate and severe essential hypertension treated in the Weining Yi Hui Miao Autonomous County People’s Hospital From September 2022 to September 2023 were selected as the study objects and randomly divided into a study group and a control group,with 35 cases in each group.The study group was treated with Felodipine Sustained-Release Tablets combined with Lisinopril Hydrochlorothiazide Tablets,and the control group was treated with Felodipine Sustained-Release Tablets combined with Benazepril and Hydrochloride Tablets.The blood pressure level,the total effective rate and the occurrence of adverse reactions were compared between the two groups.Results:After six months of treatment,the systolic blood pressure(123.58±10.36)mmHg and diastolic blood pressure(80.14±5.07)mmHg of the study group were lower than(162.37±15.24)mmHg and(94.02±90.18)mmHg of the control group,the total effective rate 97.14%of the study group was higher than 82.86%of the control group,the incidence of adverse reactions 2.86%in the study group was lower than 14.29%in the control group,the differences were statistically significant(P<0.05).Conclusion:The Felodipine Sustained-Release Tablets Combined with Lisinopril and Hydrochlorothiazide Tablets in the treatment of patients with moderate and severe essential hypertension can achieve good therapeutic effect,obvious blood pressure reduction,and has certain safety.

关 键 词：中重度原发性高血压 赖诺普利氢氯噻嗪片 疗效 安全性 

分 类 号：R453[医药卫生—治疗学]